Related Experiment Video

Updated: Jun 23, 2026

FISH for Pre-implantation Genetic Diagnosis
07:34

FISH for Pre-implantation Genetic Diagnosis

Published on: February 24, 2011

Preimplantation genetic diagnosis for cancer

Martinus F Niermeijer, Guido de Wert, Wybo Dondorp

    The Lancet. Oncology
    |October 3, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
    09:03

    Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

    Published on: August 25, 2019

    Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
    09:30

    Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

    Published on: August 17, 2022

    Related Experiment Videos

    Last Updated: Jun 23, 2026

    FISH for Pre-implantation Genetic Diagnosis
    07:34

    FISH for Pre-implantation Genetic Diagnosis

    Published on: February 24, 2011

    Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
    09:03

    Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

    Published on: August 25, 2019

    Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
    09:30

    Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

    Published on: August 17, 2022

    Related Concept Videos

    Genetic Screens02:46

    Genetic Screens

    Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
    Forward genetic screens
    Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...

    Articles linked to this work by shared authors, journal, and citation graph.

    Towards responsible genome-wide screening: normative and stakeholder considerations.

    European journal of human genetics : EJHG·2026

    Facing suffering honestly: On severity, utility, and the public good in reproductive genetic carrier screening.

    European journal of human genetics : EJHG·2026

    Cascade counselling and testing. Recommendations of the European Society of Human Genetics.

    European journal of human genetics : EJHG·2025

    [Multi-cancer screening? A proactive ethical exploration].

    Nederlands tijdschrift voor geneeskunde·2025

    Towards responsible ctDNA-based multi-cancer screening: a preliminary exploration and discussion of ethically relevant aspects.

    Extracellular vesicles and circulating nucleic acids·2024

    Autonomy and prevention: From conflicting to complementary aims of prenatal screening.

    Bioethics·2024

    Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

    The Lancet. Oncology·2026

    Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

    The Lancet. Oncology·2026

    Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

    The Lancet. Oncology·2026

    Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.

    The Lancet. Oncology·2026

    High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial.

    The Lancet. Oncology·2026

    SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial.

    The Lancet. Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us